Avadel Pharmaceuticals (FRA:AWK1) Short-Term Capital Lease Obligation

: €1.02 Mil (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

Avadel Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2022 was €1.02 Mil.

Avadel Pharmaceuticals's quarterly Short-Term Capital Lease Obligation increased from Mar. 2022 (€0.83 Mil) to Jun. 2022 (€0.88 Mil) and increased from Jun. 2022 (€0.88 Mil) to Sep. 2022 (€1.02 Mil).

Avadel Pharmaceuticals's annual Short-Term Capital Lease Obligation declined from Dec. 2019 (€0.58 Mil) to Dec. 2020 (€0.39 Mil) but then increased from Dec. 2020 (€0.39 Mil) to Dec. 2021 (€0.80 Mil).

Avadel Pharmaceuticals Short-Term Capital Lease Obligation Historical Data

The historical data trend for Avadel Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Capital Lease Obligation

0.58

0.39

0.80

Avadel Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Short-Term Capital Lease Obligation																0.43	0.80	0.83	0.88	1.02

Avadel Pharmaceuticals Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Avadel Pharmaceuticals Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (FRA:AWK1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK1) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Avadel Pharmaceuticals (FRA:AWK1) Headlines

No Headlines